Top

International Journal of Colorectal Disease

Published in:

01-03-2015 | Original Article

Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome

Authors: K. S. Ramcharan, G. Y. H. Lip, P. S. Stonelake, A. D. Blann

Published in: International Journal of Colorectal Disease | Issue 3/2015

Abstract

Introduction

The endothelium and angiogenesis are therapeutic targets in cancer. Response to treatment may be assessed by laboratory plasma markers such as circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), von Willebrand factor (vWf), soluble E selectin, vascular endothelial growth factor (VEGF) and angiogenin. We hypothesised that these markers, obtained before surgery, would predict 2-year outcome after surgery with or without anti-angiogenic therapy for colorectal cancer (CRC).

Methods

We recruited 154 patients with CRC, of whom 51 were treated with surgery alone, 74 were treated with standard chemotherapy (5-fluorouracil) and 29 were treated with standard chemotherapy plus anti-VEGF therapy (Avastin). Peripheral blood was taken before surgery. CD34⁺/CD45⁻/CD146⁺ CECs and CD34⁺/CD45⁻/CD309 [KDR]⁺ EPCs were measured by flow cytometry and plasma markers by ELISA.

Results

After a mean of 2.1 years follow-up (range 1.9–2.3 years), 52 of the patients (33.7 %) experienced a poor outcome (radiological and/or histological evidence of tumour spread or recurrence, or death [n = 26]). In univariate analysis, poor outcome was linked to Dukes’ stage (p < 0.001), American Joint Committee on Cancer (AJCC) stage (p < 0.001), type of treatment (surgery alone, standard chemotherapy with or without anti-antigenic therapy) (p = 0.047), CECs (p < 0.02) and EPCs (p < 0.01). In subsequent binary logistic regression analysis, only Dukes’ stage (hazard ratio 2.3, 95 % confidence interval 1.0–5.3, p = 0.047) and modified AJCC stage (4.62, 1.88–11.33, p < 0.001) predicted a poor outcome.

Conclusion

Endothelial cell markers (CECs, EPCs, vWf, soluble E selectin) and growth factors (VEGF and angiogenin), measured before surgery, have nothing extra to offer in predicting 2-year outcome in colorectal cancer when compared to Dukes’ or AJCC stage.

Cancer Research UK: http://info.cancerresearchuk.org/utilities/atozindex/atoz-bowel-cancer

Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990:824–6

Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964–8PubMed

Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M (1999) Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 5:1125–30PubMed

Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, Kalofonos HP (2011) Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem 18:1599–612CrossRefPubMed

Gil-Bazo I, Catalán GV, Gutiérrez A, Rodríguez J, Páramo FJA et al (2005) Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol 7:150–5CrossRefPubMed

Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M, Maeda K (2010) Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol 40:1073–80CrossRefPubMed

Dome D, Dobos J, Tovari J, Paku S, Kovacs G, Ostoros G, Timar J (2008) Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 73:186–93CrossRefPubMed

Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen L (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71:105–13CrossRefPubMed

10.

Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J, Boneberg EM (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94:524–31CrossRefPubMedCentralPubMed

11.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15:139–45CrossRefPubMed

12.

Blann AD, Pretorius A (2006) Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? Atherosclerosis 188:12–8CrossRefPubMed

13.

Ding YT, Kumar S, Yu DC (2008) The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 75:265–73CrossRefPubMed

14.

Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 79:224–8CrossRefPubMed

15.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–42CrossRefPubMed

16.

Blann AD, Ramcharan KS, Stonelake PS, Luesley D, Lip GY (2011) The angiome: a new concept in cancer biology. J Clin Pathol 64:637–43CrossRefPubMed

17.

Ramcharan KS, Lip GY, Stonelake PS, Blann AD (2011) The endotheliome: a new concept in vascular biology. Thromb Res 128:1–7CrossRefPubMed

18.

Ramcharan SK, Lip GYH, Stonelake PS, Blann AD (2013) Angiogenin outperforms VEGF, EPCs and CECs in predicting Duke’s stage in colorectal cancer. Eur J Clin Invest 43:801–8CrossRefPubMed

19.

Dukes CE (1932) The classification of cancer of the rectum. J Pathol Bacteriol 35:323CrossRef

20.

Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:84–6CrossRef

21.

Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–12CrossRefPubMed

22.

Cheeseman SL, Joel SP, Chester JD et al (2002) A ‘modified de Gramont’ regimen of fluorouracil, alone and with Oxaliplatin, for advanced colorectal cancer. Br J Cancer 87:393–9CrossRefPubMedCentralPubMed

23.

André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–51CrossRefPubMed

24.

André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–16CrossRefPubMed

25.

Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–704CrossRefPubMed

26.

Goon PK, Lip GY, Stonelake PS, Blann AD (2009) Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 11:771–9PubMedCentralPubMed

27.

Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY (2011) Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate 71:1047–53CrossRefPubMed

28.

ACPGBI 2007. http://www.acpgbi.org.uk/content/uploads/2007-CC-Management-Guidelines.pdf

29.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47CrossRefPubMed

30.

Parulekar WR, Eisenhauer EA (2002) Novel endpoints and design of early clinical trials. Ann Oncol 13(Suppl 4):139–43CrossRefPubMed

31.

Kemeny N, Braun DW Jr (1983) Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 74:786–94CrossRefPubMed

32.

Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K (2011) Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer 117:4026–32CrossRefPubMed

33.

Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K et al (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 21:2382–9CrossRefPubMed

34.

Gupta M (2007) Circulating endothelial cells and circulating endothelial cell progenitors as surrogate markers for determining response to antiangiogenic agents. Clin Colorectal Cancer 6:337–8CrossRefPubMed

35.

Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, Young PP (2006) VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20:1495–7CrossRefPubMed

36.

Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964–72CrossRefPubMedCentralPubMed

37.

Bellows CF, Zhang Y, Chen J, Frazier ML, Kolonin MG (2011) Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 20:2461–8CrossRefPubMed

38.

Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K (1998) Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 93:249–52CrossRefPubMed

39.

Werther K, Christensen IJ, Brünner N, Nielsen HJ (2000) Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26:657–62CrossRefPubMed

40.

De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270–8CrossRefPubMed

41.

Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J et al (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279–85PubMed

Title: Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome
Authors: K. S. Ramcharan
G. Y. H. Lip
P. S. Stonelake
A. D. Blann
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 3/2015
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-014-2116-3

At a glance: The STEP trials

Springer Medicine

Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Management of nodal disease from colon cancer in the laparoscopic era

Staged seton fistulotomy after restorative proctocolectomy with ileal pouch–anal anastomosis accompanied by a decline in anal pressure during manometry

Water soluble contrast enema examination of the integrity of the rectal anastomosis prior to loop ileostomy reversal may be superfluous

Long-term results after endoanal advancement flap repair for fistulas-in-ano. How important is the aetiology?

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer